Emedgene, an Illumina Company
Unlock genomic insights
Unlock genomic insights
Emedgene, an Illumina Company, founded in 2015, is dedicated to unlocking genomic insights for the world’s health organizations. The company provides data-driven AI solutions for genomic diagnostics and discovery at scale, operating within the biotechnology, health care, and information technology industries. Based in the United States, Emedgene works with leading healthcare and life sciences organizations to enable precision medicine programs, high throughput diagnostics, and accelerate research.
The latest funding round saw $6.00M Series A investment from OTV on 19 February 2019. This capital injection underlines the confidence that investors have in Emedgene's mission and technology. With its focus on leveraging AI for genomic insights, Emedgene is well-positioned to make a significant impact in the healthcare and life sciences sectors, driving advancements in personalized medicine and diagnostic efficiency.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $6.00M | 1 |
|
19 Feb 2019 |
| Seed Round | Unknown | 1 | Yaron Samid | 01 Oct 2017 |
| Seed Round | Unknown | 1 |
|
14 Aug 2017 |
No recent news or press coverage available for Emedgene, an Illumina Company.
We care about your data, and we'd love to use cookies make your experience better.
